Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
IFI-35 CRISPR/Cas9 KO Plasmid (h): sc-406072
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- IFI-35 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the IFI-35 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: IFI-35 Antibody (B-1): sc-393513
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
IFI-35 CRISPR/Cas9 KO Plasmid (h) | sc-406072 | 20 µg | $397.00 |
Overview
IFI35 encodes IFI-35, an interferon-stimulated protein that participates in innate immune signaling and modulation of inflammatory gene expression. IFI-35 is linked to type I interferon responses and has been reported to interact with immune regulatory proteins, influencing pathways downstream of pattern-recognition receptor activation such as RIG-I–like receptor and TLR signaling. Through these networks, IFI35 contributes to antiviral defense programs and can affect cytokine outputs, antigen presentation, and broader immune cell activation states. Dysregulated interferon signaling and altered IFI35 expression have been associated with immune-mediated pathology and tumor–immune interactions, supporting its relevance in studies of inflammation, infection biology, and cancer immunology.
IFI-35 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the IFI35 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the IFI35 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the IFI35 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish IFI-35 protein expression.
This CRISPR knockout system enables efficient generation of IFI35-deficient cell models for investigation of IFI-35 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting IFI35 exon(s) critical for IFI-35 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple IFI35 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by IFI-35 CRISPR/Cas9 KO Plasmid (h) and IFI-35 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the IFI35 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by IFI-35 HDR Plasmid (h) and IFI-35 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by IFI35 homology arms to support homology-directed repair at defined IFI35 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.